John H Alexander

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Electronic address
    Am Heart J 166:559-65. 2013
  2. doi request reprint The safety and efficacy of apixaban : where do we stand in 2013?
    Flavio de Souza Brito
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Expert Opin Drug Saf 12:559-67. 2013
  3. ncbi request reprint Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2446-54. 2005
  4. doi request reprint Apixaban with antiplatelet therapy after acute coronary syndrome
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:699-708. 2011
  5. doi request reprint The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27715, USA
    Cleve Clin J Med 76:S16-23. 2009
  6. doi request reprint Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA
    Circulation 119:2877-85. 2009
  7. doi request reprint Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    JAMA 299:1777-87. 2008
  8. ncbi request reprint The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 150:643-9. 2005
  9. ncbi request reprint Inhibition of Factor Xa : a potential target for the development of new anticoagulants
    John H Alexander
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Cardiovasc Drugs 5:279-90. 2005
  10. doi request reprint Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:235-44. 2009

Collaborators

Detail Information

Publications81

  1. doi request reprint Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Electronic address
    Am Heart J 166:559-65. 2013
    ..3% of subjects in the apixaban group and 1.2% of subjects in the warfarin group received, at some point during the study, a container of the wrong type."..
  2. doi request reprint The safety and efficacy of apixaban : where do we stand in 2013?
    Flavio de Souza Brito
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA
    Expert Opin Drug Saf 12:559-67. 2013
    ..We reviewed the pharmacokinetics and pharmacology as well as the clinical safety and efficacy of apixaban , an oral direct factor Xa inhibitor...
  3. ncbi request reprint Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:2446-54. 2005
    ..Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure...
  4. doi request reprint Apixaban with antiplatelet therapy after acute coronary syndrome
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:699-708. 2011
    ..Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome...
  5. doi request reprint The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27715, USA
    Cleve Clin J Med 76:S16-23. 2009
    ..More evidence-based use of existing and emerging antiplatelet agents has the potential to improve both ischemic and bleeding outcomes in patients with ACS...
  6. doi request reprint Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA
    Circulation 119:2877-85. 2009
    ..After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding...
  7. doi request reprint Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    JAMA 299:1777-87. 2008
    ..Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery...
  8. ncbi request reprint The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics
    John H Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 150:643-9. 2005
    ..Edifoligide inhibits E2F, a transcription factor that activates cell-cycle genes responsible for neointimal hyperplasia...
  9. ncbi request reprint Inhibition of Factor Xa : a potential target for the development of new anticoagulants
    John H Alexander
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Cardiovasc Drugs 5:279-90. 2005
    ..Ongoing investigation with numerous oral and parenteral inhibitors of Factor Xa will establish the potential of Factor Xa as a target for therapeutic anticoagulation...
  10. doi request reprint Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:235-44. 2009
    ....
  11. pmc Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
    Circulation 125:749-56. 2012
    ..In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angiography 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes...
  12. ncbi request reprint Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 95:1404-8. 2005
    ..All MI types were associated with worse short- and long-term outcomes. Characterization of the type of MI provides an opportunity for more informed interpretation of clinical trial results and improved planning for future trials...
  13. pmc Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
    Connie N Hess
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 164:607-15. 2012
    ..Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is important...
  14. doi request reprint Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial
    Rajendra H Mehta
    Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
    Circulation 124:280-8. 2011
    ....
  15. doi request reprint Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 109:320-6. 2012
    ..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI...
  16. doi request reprint Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 159:331-9. 2010
    ....
  17. ncbi request reprint Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..A concomitant goal was to contribute insight to the debate over how patients with NSTE ACS should be managed...
  18. pmc Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results
    Renato D Lopes
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 164:379-386.e1. 2012
    ..We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes...
  19. doi request reprint Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
    James M Yau
    Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 102:546-51. 2008
    ..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
  20. ncbi request reprint Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy
    Trip J Meine
    Division of Cardiology, Department of Medicine, Duke University, Durham, NC 27715, USA
    Am Heart J 149:670-4. 2005
    ..We sought to delineate predictors of AVB and determine long-term mortality of patients developing AVB in the setting of ST-segment elevation MI (STEMI) treated with thrombolytic therapy...
  21. doi request reprint Apixaban versus warfarin in patients with atrial fibrillation
    Christopher B Granger
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:981-92. 2011
    ..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin...
  22. doi request reprint Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
    J Thorac Cardiovasc Surg 136:1149-55. 2008
    ..Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery...
  23. doi request reprint Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome
    Richard C Becker
    Division of Cardiology and Hematology, Duke University School of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Thromb Haemost 104:976-83. 2010
    ..5 mg twice daily dose. The effect on both D-dimer and F 1.2 was apixaban concentration-and factor Xa inhibition dependent, durable and provided general guidance for dose selection in phase 3 investigation...
  24. pmc Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction
    Jonathan P Piccini
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Crit Care Med 39:78-83. 2011
    ..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
  25. doi request reprint A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 155:600-8. 2008
    ....
  26. doi request reprint Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches
    Sumeet Subherwal
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 165:644-54, 654.e1. 2013
    ..We describe alternative statistical approaches for concurrent assessment of the safety and efficacy of antithrombotic therapies used to treat patients with NSTE ACS...
  27. doi request reprint Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Lancet 380:1749-58. 2012
    ..We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding...
  28. doi request reprint Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
    Mark Y Chan
    Duke Clinical Research Institute, 2400 Pratt St, Terrace Level Room 0311, Durham, NC 27705, USA
    Circulation 117:2865-74. 2008
    ..REG1 consists of RB006 (drug), an injectable RNA aptamer that specifically binds and inhibits factor IXa, and RB007 (antidote), the complementary oligonucleotide that neutralizes its anti-IXa activity...
  29. ncbi request reprint Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery
    Abdul R Halabi
    Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1254-9. 2005
    ..36, 95% confidence interval 2.00 to 2.79, p <0.0001). In conclusion, in contemporary clinical practice, early SVG failure is associated with worse long-term outcomes after CABG...
  30. doi request reprint Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Am J Med 124:48-57. 2011
    ....
  31. ncbi request reprint Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery
    Abhinav Goyal
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Thorac Surg 83:993-1001. 2007
    ..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
  32. ncbi request reprint Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials
    Kenneth W Mahaffey
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA, and Catholic University Hospital, Leuven, Belgium
    Eur Heart J 28:425-32. 2007
    ..To assess the significance of creatine kinase (CK)-MB elevations in outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who have undergone coronary artery bypass grafting (CABG) surgery...
  33. ncbi request reprint Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes
    Abdallah G Rebeiz
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Med 116:119-29. 2004
    ..We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization...
  34. doi request reprint Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor
    Richard C Becker
    Division of Cardiology, Duke University School of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Advanced Biomarker Program, 2400 Pratt Street, Durham, NC 27705, USA
    J Thromb Thrombolysis 32:183-7. 2011
    ..While establishing parameters for safety and efficacy will require further investigation, an ability to discern the presence of a drug effect may provide clinically useful information...
  35. doi request reprint Promise of factor Xa inhibition in atrial fibrillation
    Sana M Al-Khatib
    Division of Cardiology, Department of Medicine, Duke Clinical Research Institute and Duke University, 2400 Pratt Street, PO Box 17969, Durham, NC 27705, USA
    Curr Cardiol Rep 14:70-8. 2012
    ....
  36. doi request reprint Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy
    Thomas J Povsic
    Department of Medicine, Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Box 103208, Durham, NC 27710, USA
    Eur Heart J 32:2412-9. 2011
    ..The REG1 system (Regado Biosciences, Basking Ridge, NJ) consists of pegnivacogin (RB006), an RNA aptamer that directly inhibits factor IXa, and anivamersen (RB007), its complementary control agent...
  37. ncbi request reprint Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy
    Rajendra H Mehta
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:1371-5. 2005
    ..962 (95% CI 0.896 to 1.033). These data indicate that height-related differences in 30-day mortality are explained in large part by height-related differences in patients' clinical characteristics...
  38. doi request reprint Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Thromb Thrombolysis 32:242-66. 2011
    ..This paper summarizes the symposium proceedings...
  39. doi request reprint Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 158:792-8. 2009
    ..Current practice related to the management of atrial fibrillation (AF) complicating coronary artery bypass grafting (CABG) is uncertain...
  40. doi request reprint Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting
    Judson B Williams
    Duke Clinical Research Institute, Durham, NC, USA
    J Thromb Thrombolysis 36:384-93. 2013
    ..There may be better outcomes with clopidogrel among patients having off-pump surgery. Adequately powered randomized clinical trials are needed to determine the role of dual antiplatelet therapy after CABG...
  41. pmc Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery
    Judson B Williams
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 308:475-84. 2012
    ..The safety and durability of endoscopic vein graft harvest in coronary artery bypass graft (CABG) surgery has recently been called into question...
  42. ncbi request reprint Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
    JAMA 293:1746-50. 2005
    ..Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship...
  43. doi request reprint Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease
    Aslan T Turer
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    J Thorac Cardiovasc Surg 137:1468-74. 2009
    ..We examined the effect of body mass index on the association between revascularization strategy and survival in patients with coronary artery disease...
  44. doi request reprint A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial
    Thomas J Povsic
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Eur Heart J 34:2481-9. 2013
    ..REG1 has not been studied in invasively managed patients with ACS nor has an optimal level of reversal allowing safe sheath removal been defined...
  45. ncbi request reprint Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
    Richard E Waters
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 43:2153-9. 2004
    ..Consequently, this current evolution of reperfusion strategies has the potential to further reduce morbidity and mortality for patients presenting with STEMI...
  46. doi request reprint Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial
    John H Alexander
    Duke Clinical Research Institute, Duke Medicine, Duke University Medical Center, Box 3850, Durham, NC 27710, USA
    Eur Heart J 35:224-32. 2014
    ..We assessed the effect of concomitant aspirin use on the efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation (AF)...
  47. doi request reprint Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions
    Ralf E Harskamp
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Ann Surg 257:824-33. 2013
    ..To review our current understanding of the epidemiology and pathogenesis of vein graft failure (VGF), give an overview of current preventive and interventional measures, and explore strategies that may improve vein graft patency...
  48. doi request reprint Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician
    Connie N Hess
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Box 3850, Durham, NC 27705, USA
    J Thromb Thrombolysis 34:552-61. 2012
    ..We provide a review of the clinical syndrome and practical summary of treatment recommendations from the most recent 2012 American College of Chest Physicians evidence-based guidelines for the treatment and prevention of HIT...
  49. ncbi request reprint Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor
    Richard C Becker
    Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, NC 27705, USA
    J Thromb Thrombolysis 18:193-7. 2004
    ....
  50. ncbi request reprint Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease
    Salvador Borges-Neto
    Department of Medicine Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Cardiol 95:182-8. 2005
    ..This information may be useful for stratifying patients into multiple risk categories for future cardiovascular events and potentially guiding therapy...
  51. ncbi request reprint Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial
    John H Alexander
    Duke University, Durham, NC, USA
    JAMA 297:1657-66. 2007
    ..Preliminary, single-center studies suggested a beneficial effect of NOS inhibition on hemodynamics, renal function, and survival in patients with cardiogenic shock...
  52. doi request reprint Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 121:1713-21. 2010
    ..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
  53. pmc The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial
    John P Vavalle
    Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 162:996-1002. 2011
    ..Eptifibatide dosing is weight adjusted for patients up to 121 kg. Patients above this weight receive the same maximal dose, although it is unknown if this provides adequate eptifibatide concentration or platelet inhibition...
  54. doi request reprint Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician
    S Michael Gharacholou
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 29:516-28. 2010
    ....
  55. doi request reprint Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock
    Sean van Diepen
    1Divisions of Critical Care and Cardiology, University of Alberta, Edmonton, Alberta, Canada 2Cardiovascular Clinical Research Center, New York University School of Medicine, New York, NY 3Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 4Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada 5Institute of Cardiology, Warsaw, Poland 6Wilhelminen Hospital, Vienna, Austria 7Third Faculty of Medicine, Charles University Prague, Czech Republic 8Robert Wood Johnson Medical School and Cooper University Hospital, Camden, NJ 9University of Vermont, Burlington, VT 10Newark Beth Israel Medical Center, Newark, NJ
    Crit Care Med 42:281-8. 2014
    ..The prevalence and outcomes associated with β and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown...
  56. doi request reprint Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Thromb Thrombolysis 26:167-74. 2008
    ....
  57. ncbi request reprint Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes
    John H Alexander
    Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    Am J Med 115:613-9. 2003
    ..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome...
  58. doi request reprint Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Eur Heart J 34:2464-71. 2013
    ..It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF)...
  59. doi request reprint Saphenous vein graft failure and clinical outcomes: Toward a surrogate end point in patients following coronary artery bypass surgery?
    Ralf E Harskamp
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am Heart J 165:639-43. 2013
    ..Given the lack of supportive evidence showing a consistent association between SVG failure and major adverse cardiovascular events, SVG failure should not be considered a valid surrogate endpoint at this time...
  60. ncbi request reprint First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
    Christopher K Dyke
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 114:2490-7. 2006
    ..The primary objective was to determine the safety profile and to characterize the pharmacodynamic responses in this first-in-human study...
  61. pmc Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies
    Benjamin A Steinberg
    Duke Center for Atrial Fibrillation, Electrophysiology Section, Duke University Medical Center, Durham, NC, USA
    J Interv Card Electrophysiol 37:213-21. 2013
    ..Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). The safety and effectiveness of periprocedural dabigatran in ablation for AF are unknown...
  62. doi request reprint Novel oral anticoagulants after acute coronary syndromes
    Newton B Wiggins
    Duke University Medical Center, Durham, NC 27715, USA
    Cardiovasc Drugs Ther 26:265-71. 2012
    ..This review discusses these agents and their respective clinical trials in patients with acute coronary syndromes...
  63. doi request reprint Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials Network
    Peter K Smith
    Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC, USA
    J Thorac Cardiovasc Surg 143:111-7, 117.e1. 2012
    ..The optimal treatment of this condition has become increasingly controversial, and a randomized trial evaluating current practices is warranted...
  64. doi request reprint Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician
    Anandi Krishnan
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 27710, Durham, NC, USA
    J Thromb Thrombolysis 29:368-77. 2010
    ..Future directions are also reviewed, with particular emphasis on improving therapeutic options early after stroke onset...
  65. ncbi request reprint Hand-held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30-day outcome associated with normal left ventricular wall motion
    Patrick Weston
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 148:1096-101. 2004
    ....
  66. ncbi request reprint Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?
    Masaya Koshizaka
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circ J 76:1572-80. 2012
    ....
  67. ncbi request reprint Feasibility of point-of-care echocardiography by internal medicine house staff
    John H Alexander
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 147:476-81. 2004
    ..To determine whether internal medicine house staff with limited training in echocardiography can use point-of-care echocardiography to make simple, clinically important diagnoses...
  68. doi request reprint A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction
    Thomas J Povsic
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 162:654-662.e1. 2011
    ..We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in patients with heart failure (HF)...
  69. doi request reprint A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase
    Thomas J Povsic
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 161:261-268.e1-2. 2011
    ....
  70. doi request reprint Prophylaxis for venous thromboembolism: guidelines translated for the clinician
    Gregg Stashenko
    Duke Clinical Research Institute, Duke University Medical Center, Box 3850, Durham, NC 27710, USA
    J Thromb Thrombolysis 31:122-32. 2011
    ..In addition, we will discuss recent clinical trials regarding novel anticoagulants for venous thromboembolism prophylaxis and share some conclusions...
  71. ncbi request reprint Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?
    K Martijn Akkerhuis
    Thoraxcenter, University Hospital Rotterdam, The Netherlands
    Circulation 105:554-6. 2002
    ....
  72. ncbi request reprint Screening for structural heart disease: time to stop listening and start looking
    John H Alexander
    Am Heart J 146:570-1. 2003
  73. doi request reprint Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters
    Stephen A Olenchock
    Cardiothoracic Surgery Department, Tufts University School of Medicine and Caritas St Elizabeth s Medical Center, Boston, Massachusetts, USA
    Ann Thorac Surg 85:520-4. 2008
    ..The goal of the present analysis was to evaluate the association of SVG markers with clinical outcomes and graft patency...
  74. doi request reprint Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV
    Mitchell J Magee
    Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, USA
    Ann Thorac Surg 85:494-9; discussion 499-500. 2008
    ....
  75. ncbi request reprint Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial
    Marc Cohen
    Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
    Circulation 115:2642-51. 2007
    ..Otamixaban, a selective and direct inhibitor of factor Xa, was investigated in patients undergoing nonurgent percutaneous coronary intervention...
  76. ncbi request reprint Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy
    Victor L Serebruany
    Sinai Hospital, Johns Hopkins University, Baltimore, MD, USA
    Am Heart J 145:636-42. 2003
    ..Therefore, the success of fibrinolytic therapy may be dependent on its direct effects on platelets...
  77. ncbi request reprint Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy
    Lene H Madsen
    Department of Cardiology and Endocrinology, Frederiksberg University Hospital, Copenhagen, Denmark
    Circ Res 99:1141-7. 2006
    ..Infarct size and time to initiation of treatment was the major determinant for degradation...
  78. ncbi request reprint Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction
    Peter R Sinnaeve
    Department of Cardiology, University of Leuven, Leuven, Belgium
    Am Heart J 147:993-8. 2004
    ..The aim of the present study was to determine the effect of these fibrinolytic regimens on 1-year mortality...
  79. ncbi request reprint Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)
    Jeptha P Curtis
    Yale University School of Medicine, New Haven, Connecticut, USA
    Am J Cardiol 94:279-83. 2004
    ..49, 95% CI 0.35 to 0.67) than did patients in ASSENT-2. These findings support the use of smaller dose, weight-adjusted heparin in patients with ST-elevation myocardial infarction treated with tenecteplase...
  80. ncbi request reprint Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials
    John H Alexander
    Curr Cardiol Rep 8:279-81. 2006
  81. ncbi request reprint Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study
    Vladimir Dzavik
    University Health Network, Toronto General Hospital, 6 246, 200 Elizabeth Street, Toronto M5G 2C4, Ontario, Canada
    Eur Heart J 28:1109-16. 2007
    ..We assessed preliminary efficacy and safety of four doses of l-n-monomethyl-arginine (l-NMMA), a non-selective NOS inhibitor, in patients with AMI complicated by CS despite an open infarct-related artery...